Multiple studies have confirmed the efficacy and safety of several PD-1 inhibitors in the treatment of advanced GC, and these studies provide further support for PD-1 inhibitors as the first-line treatment in advanced GC (4, 6, 7). The gene discussed is PDCD1; the disease is gastric cancer.